
EDITORIAL: We estimate that Rochester has a lot of work to do to regain public trust in its estimates
Mar. 15—Rochester's elected leaders, as well as the city's professional administrators and planners, are taking some well-deserved heat right now regarding the ballooning projected cost of a taxpayer-funded sports complex on the city's southeast side.
That heat is well-deserved — but in retrospect, signs of potential trouble were evident months before voters went to the polls to sign off on the project.
In July 2023, the city released a 148-page study on the Regional Sports & Recreation Complex . This document covered a lot of ground, but for today's purposes, we refer readers to page 74, on which is found a Summary of Development Costs. Three possible price tags are listed for the combined costs of land acquisition, construction, furnishings and equipment: Low — $65.1 million; Mid — $74.2 million; and High — $81.3 million.
Voters who went to the polls six months later to approve an extension of the city's local-option sales tax had the "Low" price tag in mind. The ballot question earmarked $65 million for the sports complex, and that's the figure Rochester residents had heard repeatedly in the run-up to the vote. If anyone was talking about a possible $81 million price for the complex, they weren't being heard.
It turns out that even that higher figure would not qualify as a good ballpark estimate. Current cost projections stand at $120 million, and the final number might keep growing.
We wish we could shrug our shoulders and call this a one-off, an outlier, a case in which our leaders' best efforts were undone by unforeseen circumstances, but we can't. This funding gap is part of a disturbing pattern that gives Rochester residents ample reason to scoff when city officials talk about the likely costs of any future projects — as well as the benefits, financial and otherwise, that those projects might yield.
For example, the Link Bus Rapid Transit system was initially projected to cost $114 million, but that price has grown to $175 million — and the current bidding process isn't providing much assurance that costs won't keep rising. Local taxpayers won't pick up the tab for these extra costs, but if you're compiling a list of Rochester projects that keep getting pushed back as their price tags rise, this one is near the top.
Then there are two problem areas — some might call them money pits — in the heart of downtown Rochester. The Peace Plaza renovation, known as the "Heart of the City" project, cost $19.4 million in state-provided Destination Medical Center funds. The end product is at best underwhelming, has required a lot of maintenance and repairs, and might ultimately need to be completely redone.
Some of the plaza's much-talked-about paving stones lie in the shadow of another problem property — the Chateau Theater. Formerly an iconic part of the downtown scene, the site has been in limbo since the city purchased it a decade ago for $6 million. Rochester has invested another $4.4 million in plumbing, electrical repairs and acoustic upgrades, yet the Chateau seems little closer to a final, functional form than it was 10 years ago.
We could go on (don't get us started on when or if the $84 million expansion of Mayo Civic Center will pay for itself), but you get the idea. At the moment, Rochester seems to have a habit of being overly optimistic, then being caught off-guard when reality hits.
Granted, these are unusual times. A global pandemic took a heavy toll on Rochester's tourism economy. A post-COVID spike in inflation caused material costs to soar, and when Mayo Clinic announced its "Bold. Forward. Unbound." plan in November 2023 (after voters approved the sports complex funding), it instantly changed the construction environment in Rochester. Until Mayo's expansion is complete, the clinic will claim the lion's share of the region's carpenters, electricians, concrete workers and other skilled trades workers.
And now we must worry about tariffs and trade wars.
But Rochester needs to expect the unexpected as it considers expensive future projects that will take years to bring to fruition. Whatever a project might cost if it were being built today, it will cost significantly more when the first yard of concrete is poured 18 months from now. Stuff happens.
We're not accusing anyone of deliberate deception, but we can accuse the city of sloppiness and complacency, especially regarding the sports complex. Our leaders painted a pleasing-yet-fuzzy picture, then said, "We'll flesh out the details after we have the money." Rochester voters tend to give its leaders the benefit of the doubt, and that's what the city was counting on.
In retrospect, the Post Bulletin's editorial board probably should have protested, but we didn't. We, like a majority of voters, accepted that fuzzy picture at face value — and we now realize that our trust was misplaced.
We're not ready to tear up plans for the sports complex and go back to square one, but we're far from alone in at least considering that option. The mere fact that we're talking about such a possibility is proof that Rochester's leaders have a lot of work to do to regain the public's trust.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio


Business Upturn
20 hours ago
- Business Upturn
RailTel partners with Techno Electric to set ip 10MW Data Centre in Noida
By Aman Shukla Published on June 1, 2025, 15:34 IST RailTel Corporation of India Ltd. has announced the selection of M/s Techno Electric & Engineering Co. Ltd. (TECL) as its Managed Service Data Centre Partner. This strategic partnership, finalized through an open tender process, involves the development of a 10MW Data Centre in phases on RailTel's land located in Noida. A Letter of Intent (LOI) has already been issued to TECL, marking the commencement of this long-term collaboration. Under the terms of the LOI, TECL will develop the Data Centre in phases on land provided by RailTel in Noida. RailTel will receive a share of the revenue generated from the operations of the Data Centre, calculated on a fixed percentage basis. The duration of the agreement is 30 years, including the implementation phase, with the possibility of extension through mutual consent. As the agreement is structured around future earnings, the financial value of the contract cannot be precisely quantified at this stage. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
2 days ago
- Yahoo
MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production
MP Materials recently signed a Memorandum of Understanding with the Saudi Arabian Mining Company to develop a rare earth supply chain in Saudi Arabia, aligning with growing global demands. Despite reporting a net loss for the first quarter, the company increased its REO and NdPr production volumes. Additionally, no shares were repurchased in the recent buyback tranche, reflecting existing efforts. Over the past week, the company's share price rose by 11%, notably outperforming the market's 2% gain. Enhanced production results and the promising alliance appear to add weight to this recent upward trend amidst broader market growth. We've discovered 1 weakness for MP Materials that you should be aware of before investing here. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent Memorandum of Understanding between MP Materials and the Saudi Arabian Mining Company could significantly influence MP's growth narrative. By developing a rare earth supply chain in Saudi Arabia, the company stands to expand its reach into ex-China markets, potentially increasing revenue opportunities and enhancing production efficiency. This collaboration may further bolster MP's position by integrating strategic partnerships, which aligns well with existing efforts to enhance production capacities. Over the longer term, MP Materials' total return, including share price and dividends, was 34.34% over the past year. This performance exceeds both the broader market's return and the US Metals and Mining industry, which had varying results over the same period. While the company's share price rose by 11% in the past week, outperforming the 2% market gain, its longer-term success underscores its enhanced capabilities in navigating volatile pricing and market demands. The recent partnership news might positively impact revenue and earnings forecasts, further pushing analyst expectations. Given the increased production capabilities and expanded market access through new agreements, analysts' anticipated revenue growth of 33.6% per year could see validation. The consensus price target of US$26.69, slightly higher than the current share price of US$24.58, suggests moderate upside potential, indicating that the market views the company's future prospects with cautious optimism. Nonetheless, the forecasted improvement in margins and earnings growth would be critical in achieving the price target, inviting investors to evaluate their assumptions against these predictions. Click to explore a detailed breakdown of our findings in MP Materials' financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio